.png){kind=icon}
.png){kind=icon}
Return
Bladder Cancer
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2013.0059.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Bladder cancer is the fourth most common cancer in the United States. Urothelial carcinoma that originates from the urinary bladder is the most common subtype. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide recommendations on the diagnosis and management of non muscle-invasive and muscle-invasive urothelial carcinoma of the bladder. This version of the guidelines provides extensive reorganization and updates on the principles of chemotherapy management. (JNCCN 2013;11:446-475)
Keywords:
TRANSITIONAL-CELL CARCINOMA
BACILLUS-CALMETTE-GUERIN
PHASE-II TRIAL
REPEAT TRANSURETHRAL RESECTION
GEMCITABINE PLUS CISPLATIN
LONG-TERM OUTCOMES
NEOADJUVANT CHEMOTHERAPY
MITOMYCIN-C
IN-SITU
ADJUVANT CHEMOTHERAPY
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations